The impact of serum concentration-guided digoxin therapy on mortality of heart failure patients: A long-term follow-up, propensity-matched cohort study.

Balázs MukMáté VámosPéter BógyiBarna SzabóMiklós DékányDénes VágányZsuzsanna MajorosTünde BorsányiGábor Zoltán DurayRóbert Gábor KissNoémi Nyolczas

Published in: Clinical cardiology (2020)

According to our propensity-matched analysis, SDC-guided digoxin therapy was associated with increased all-cause mortality in optimally treated HFrEF patients, especially with SDC ≥0.9 ng/mL. These results reinforce the expert opinion that digoxin in HFrEF can only be used among carefully selected patients with close SDC monitoring.

Keyphrases

ejection fraction
end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
type diabetes
risk factors
cardiovascular disease
clinical practice
patient reported outcomes
coronary artery disease
cell therapy
patient reported